Related Experiment Video
Updated: Sep 18, 2025
10:39
3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
18.3K
[Contraception and migraine].
Lorraine Maitrot-Mantelet1, Geneviève Plu-Bureau2
1Service de gynécologie médicale, hôpital Cochin Port-Royal, Paris, France.
La Revue Du Praticien
|June 23, 2025
Summary
Women with migraine should discuss contraception options with their doctor. Combined hormonal contraception (CHC) may be suitable for migraine without aura if no arterial risk factors are present.
Area of Science:
- Obstetrics and Gynecology
- Neurology
Context:
- Migraine is a prevalent neurological condition affecting many women of reproductive age.
- Combined hormonal contraception (CHC) use requires careful consideration in patients with migraine due to potential arterial risks.
- Arterial risk factors, including hypertension and smoking, are critical in contraceptive decision-making for migraineurs.
Purpose:
- To outline essential screening protocols for migraine and arterial risk factors before prescribing or renewing combined hormonal contraception (CHC).
- To provide clear guidelines on contraceptive choices for women with migraine, with or without aura, and varying arterial risk profiles.
- To offer management strategies for women experiencing bothersome menstrual migraine while on hormonal contraception.
Summary:
- Screening for migraine (with or without aura) and arterial risk factors is mandatory before initiating or continuing CHC.
- CHC is permissible for women with migraine without aura, provided no other arterial risk factors are present.
- CHC is contraindicated in women with migraine with aura, or with migraine without aura and any arterial risk factor; progestin-only or non-hormonal contraception is advised.
Impact:
- This guidance aims to minimize the risk of arterial thrombotic events in women using hormonal contraception and suffering from migraines.
- It promotes personalized contraceptive care, ensuring safer and more effective options for migraine patients.
- Implementing these recommendations can improve patient safety and therapeutic outcomes in managing contraception for women with migraine.
Related Concept Videos
01:22Birth Control Methods
3.1K
Vasectomy is a surgical form of male sterilization that involves severing and sealing the vasa deferentia, preventing sperm from mixing with semen during ejaculation. Because a vasectomy does not impact the testes' ability to produce testosterone, hormone levels, libido, and sexual function generally remain unchanged. While vasectomy is highly effective in preventing pregnancy, with a success rate near 99.85%, rare cases of recanalization (spontaneous reconnection) can occur. Although...
3.1K
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
330
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
330
01:19Mitral Valve Prolapse III: Nursing Management
41
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
41
01:22Hormonal Regulation of the Menstrual Cycle
725
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
725
01:27Ovarian Cycle
1.9K
The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
1.9K
01:17Hormonal Regulation of Blood Pressure
3.2K
Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
3.2K